All Stories

  1. Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma
  2. GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice
  3. Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo
  4. A niche-dependent myeloid transcriptome signature defines dormant myeloma cells
  5. N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer
  6. DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment
  7. HIF-2α Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1
  8. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress
  9. The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine-expressing myeloma cells
  10. EZH2 deletion in early mesenchyme compromises postnatal bone microarchitecture and structural integrity and accelerates remodeling
  11. Identification of Novel EZH2 Targets Regulating Osteogenic Differentiation in Mesenchymal Stem Cells
  12. Immunomodulatory Properties of Induced Pluripotent Stem Cell-Derived Mesenchymal Cells
  13. PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma
  14. Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma
  15. Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo
  16. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma
  17. SAMSN1 Is a Tumor Suppressor Gene in Multiple Myeloma
  18. Engineering Interaction between Bone Marrow Derived Endothelial Cells and Electrospun Surfaces for Artificial Vascular Graft Applications
  19. EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair
  20. Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma
  21. Prospective Histomorphometric and DXA Evaluation of Bone Remodeling in Imatinib-Treated CML Patients: Evidence for Site-Specific Skeletal Effects
  22. Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion
  23. The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation
  24. Plasma Adiponectin Levels Are Markedly Elevated in Imatinib-Treated Chronic Myeloid Leukemia (CML) Patients: A Mechanism for Improved Insulin Sensitivity in Type 2 Diabetic CML Patients?
  25. The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo
  26. Dysregulation of bone remodeling by imatinib mesylate
  27. Imatinib mesylate causes growth plate closure in vivo
  28. Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis
  29. Plant-Derived MINA-05 Inhibits Human Prostate Cancer Proliferation In Vitro and Lymph Node Spread In Vivo
  30. Androgen decreases osteoprotegerin expression in prostate cancer cells